Evidence map›Paper›PMID 36311816›Full record

ArticleCancer research communications2022

Uterine lavage identifies cancer mutations and increased

Talayeh S Ghezelayagh, Brendan F Kohrn, Jeanne Fredrickson, Enna Manhardt, Marc R Radke, Ronit Katz, Heidi J Gray, Renata R Urban, Kathryn P Pennington, John B Liao and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Talayeh S GhezelayaghDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Brendan F KohrnDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
Jeanne FredricksonDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
Enna ManhardtDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Marc R RadkeDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Ronit KatzDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Heidi J GrayDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Renata R UrbanDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Kathryn P PenningtonDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
John B LiaoDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Kemi M DollDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Elise J SimonsDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Jennifer K BurzawaDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Barbara A GoffDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Paul SpeiserMedical University of Vienna, Austria.
Elizabeth M SwisherDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Barbara M NorquistDepartment of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Rosa Ana RisquesDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
University of Washington · USMedical University of Vienna · AT

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancerR01CA259384 · NCI · UNIVERSITY OF WASHINGTON · PI RISQUES, ROSA ANA · 2021 to 2025
$2.8M
Evaluation of TP53 mutations in non-cancerous tissue as novel biomarkers of ovarian cancer risk.R21CA240885 · NCI · UNIVERSITY OF WASHINGTON · PI RISQUES, ROSA ANA · 2019 to 2020
$372k
NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA259384NCI NIH HHS R21 CA240885NCI NIH HHS T32 CA009515
6 · The paper itself

Abstract

Current screening methods for ovarian cancer (OC) have failed to demonstrate a significant reduction in mortality. Uterine lavage combined with

Indexed as

Ovarian NeoplasmsTherapeutic IrrigationClonal EvolutionFemaleHumansMutationTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53clonal expansionsovarian cancersomatic evolutionUterine lavage

Identifiers

PMID36311816
PMCPMC9615025
OpenAlexW4297381375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.